---
title: "Techtrek India Ltd (513153) — Share Price, Financials & Analysis"
symbol: "513153"
company: "Techtrek India Ltd"
canonical: "https://tapetide.com/stocks/513153"
isin: "INE892N01015"
bse_code: "513153"
sector: "Industrials"
industry: "Industrial Products"
generated_at: "2026-09-13T19:15:56.402Z"
---

# Techtrek India Ltd (513153)

Canonical page: https://tapetide.com/stocks/513153

## Company

- **BSE Code:** 513153
- **ISIN:** INE892N01015
- **Sector:** Industrials
- **Industry:** Industrial Products
- **Macro Sector:** Industrials
- **Stock Type:** EQUITY
- **Listed Since:** 2011-10-19
- **Face Value:** ₹10
- **F&O Eligible:** No
- **Website:** techtrekindialimited.com

## About

Techtrek India Limited, incorporated in India, Listed on the Bombay Stock exchange Limited, the company is engaged in a global consulting and IT Services provider company.

## Latest Price

## Key Insights

### Strengths

- Stock is trading at 0.18 times its book value

### Weaknesses

- Company has low interest coverage ratio.
- Company has a low return on equity of 0.66% over last 3 years.
- Earnings include an other income of Rs.2.13 Cr.
- Company has high debtors of 1,022 days.

## Growth Rates

| Metric | 1Y | 3Y | 5Y |
| --- | --- | --- | --- |
| net income growth | 482% | -14% | 1% |
| revenue growth | -12% | — | -30% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2013 | Jun 2013 | Sep 2013 | Dec 2013 | Mar 2014 | Jun 2014 |
| --- | --- | --- | --- | --- | --- | --- |
| Sales | 0.09 | 0 | -0.08 | 0.08 | 0.23 | 0.65 |
| Expenses | 0.17 | 0.15 | 0.2 | 0.19 | 0.49 | 0.77 |
| Operating Profit | -0.08 | -0.15 | -0.28 | -0.11 | -0.26 | -0.12 |
| OPM % | -88.89 | — | — | -137.5 | -113.04 | -18.46 |
| Other Income | 0.77 | 0.43 | 0.45 | 0.44 | 0.71 | 0.53 |
| Interest | 0.26 | 0.17 | 0.17 | 0.17 | 0.16 | 0.15 |
| Depreciation | 0.06 | 0 | 0.03 | 0.02 | 0.02 | 0.02 |
| Profit before tax | 0.37 | 0.11 | -0.03 | 0.14 | 0.27 | 0.24 |
| Tax % | 18.92 | 0 | 0 | 0 | 0 | 0 |
| Net Profit | 0.31 | 0.11 | -0.03 | 0.14 | 0.27 | 0.25 |
| EPS in Rs | 0.85 | 0.3 | -0.08 | 0.39 | 0.74 | 0.69 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | TTM |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 0.89 | 1.16 | 0 | 0.77 | 0.17 | 0.15 | 0.88 |
| Expenses | 0.24 | 0.6 | 0.45 | 0.53 | 0.73 | 0.67 | 1.65 |
| Operating Profit | 0.65 | 0.56 | -0.45 | 0.24 | -0.56 | -0.52 | -0.77 |
| OPM % | 73.03 | 48.28 | — | 31.17 | -329.41 | -346.67 | -87.5 |
| Other Income | 0.12 | 0.33 | 1.34 | 0.13 | 1.06 | 1.81 | 2.13 |
| Interest | 0.15 | 0.14 | 0 | 0.31 | 0.32 | 0.8 | 0.65 |
| Depreciation | 0.06 | 0.04 | 0.04 | 0.04 | 0.06 | 0.06 | 0.09 |
| Profit before tax | 0.56 | 0.71 | 0.85 | 0.02 | 0.12 | 0.43 | 0.62 |
| Tax % | 30.36 | 23.94 | 23.53 | 150 | 225 | 16.28 | — |
| Net Profit | 0.39 | 0.54 | 0.65 | -0.01 | -0.15 | 0.37 | 0.63 |
| EPS in Rs | 1.07 | 1.49 | 1.79 | -0.03 | -0.41 | 1.02 | 1.74 |
| Dividend Payout % | 0 | 0 | 0 | 0 | 0 | 0 | — |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 3.63 | 3.63 | 3.63 | 3.63 | 3.63 | 3.63 | 3.63 |
| Reserves | 10.53 | 11.07 | 11.72 | 11.71 | 11.57 | 10.62 | 10.8 |
| Borrowings | 2.39 | 1.7 | 2.63 | 3.86 | 3.75 | 5.46 | 5.87 |
| Other Liabilities | 1.75 | 4.35 | 3.59 | 3.48 | 4.01 | 3.26 | 3.43 |
| Total Liabilities | 18.3 | 20.75 | 21.57 | 22.68 | 22.96 | 22.97 | 23.73 |
| Fixed Assets | 15.97 | 15.94 | 17.79 | 18.96 | 19.37 | 18.19 | 17.97 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 2.33 | 4.81 | 3.78 | 3.72 | 3.59 | 4.78 | 5.76 |
| Total Assets | 18.3 | 20.75 | 21.57 | 22.68 | 22.96 | 22.97 | 23.73 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 |
| --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | — | — | — | 0.24 | 1.6 | -0.4 |
| Cash from Investing Activity | — | — | — | -1.21 | -0.52 | -0.19 |
| Cash from Financing Activity | — | — | — | -0.86 | -0.63 | 0.86 |
| Net Cash Flow | — | — | — | -1.83 | 0.45 | 0.27 |
| Free Cash Flow | — | — | — | -0.97 | 1.08 | -0.59 |
| CFO/OP | — | — | — | 100 | -289 | 77 |

### Ratios

| Item | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 |
| --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 4.1 | 3.15 | — | 142.21 | 193.24 | 1022 |
| Cash Conversion Cycle | 4.1 | 3.15 | — | 142.21 | 193.24 | 1022 |
| Working Capital Days | 114.83 | -210.82 | — | -1725.45 | -9060.59 | -7056.67 |
| ROCE % | — | 5.16 | 4.94 | 1.78 | 2.57 | 6.67 |

## Shareholding Pattern

### annual

| Category | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Dec 2025 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 72.68% | 72.93% | 72.97% | 72.97% | 69.48% | 69.61% | 69.61% | 69.61% | 69.67% | 69.74% |
| FIIs | 10.61% | 9.16% | 9.5% | 8.29% | 6.56% | 6.02% | 4.55% | 4.46% | 3.94% | 4.23% |
| DIIs | 3.13% | 5.16% | 5.48% | 6.86% | 10.97% | 11.74% | 13.32% | 15.39% | 16.43% | 16.17% |
| Public | 13.58% | 12.75% | 12.05% | 11.88% | 12.99% | 12.63% | 12.53% | 10.54% | 9.96% | 9.84% |
| No. of Shareholders | 50619 | 46853 | 41564 | 47283 | 99809 | 106437 | 99522 | 76567 | 91336 | 87000 |

### Quarterly

| Category | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 69.61% | 69.61% | 69.61% | 69.61% | 69.61% | 69.61% | 69.61% | 69.61% | 69.67% | 69.68% | 69.74% | 69.74% |
| FIIs | 4.55% | 4.34% | 4.51% | 4.52% | 4.46% | 4.32% | 3.94% | 4.17% | 3.94% | 3.96% | 4.04% | 4.23% |
| DIIs | 13.32% | 13.65% | 14.22% | 14.51% | 15.39% | 15.47% | 16.05% | 16.05% | 16.43% | 16.46% | 16.3% | 16.17% |
| Public | 12.53% | 12.39% | 11.67% | 11.36% | 10.54% | 10.61% | 10.38% | 10.17% | 9.96% | 9.91% | 9.92% | 9.84% |
| No. of Shareholders | 99522 | 97607 | 89552 | 85212 | 76567 | 74829 | 91429 | 93944 | 91336 | 89013 | 89969 | 87000 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Buy
- **Buy / Neutral / Sell:** 9 / 6 / 4

### Moving Averages — summary: **Strong Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 181.18 | Buy |
| EMA (10) | 183.92 | Buy |
| SMA (20) | 178.59 | Buy |
| EMA (20) | 180.31 | Buy |
| SMA (50) | 178.64 | Buy |
| EMA (50) | 180.83 | Buy |
| SMA (100) | 188.43 | Buy |
| EMA (100) | 193.76 | Sell |
| SMA (200) | 232.18 | Sell |
| EMA (200) | 221.92 | Sell |

### Oscillators — summary: **Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 59.8 | Neutral |
| MACD (12,26,9) | 3.42 | Buy |
| Stochastic (14,3,3) | 61.94 | Neutral |
| ADX (14) | 14.99 | Neutral |
| Williams %R (14) | -40.06 | Neutral |
| ATR (14) | 11.56 | High Volatility |
| ROC (12) | 7.49 | Buy |
| Stoch RSI (14) | 82.84 | Sell |
| UO (7,14,28) | 40.11 | Neutral |

## Filings & Documents

### Other Documents

| Date | Document |
| --- | --- |
| 7h - One-on-one meeting with Bajaj Finserv AMC on 11 March 2026 in Vadodara. | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 7h - One-on-one meeting with Bajaj Finserv AMC on 11 March 2026 in Vadodara.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/249a6874-3f16-46e1-9bc0-75a80cf919cd.pdf) |
| 7h - Incorporated Alembic Pharmaceuticals (Thailand) Co., Ltd on Mar 9, 2026; share capital Baht 3,000,000; Alembic holds 99.99%. | [Intimation Under Regulation 30 Of SEBI (LODR) Regulations, 2015 - Incorporation Of Subsidiary 7h - Incorporated Alembic Pharmaceuticals (Thailand) Co., Ltd on Mar 9, 2026; share capital Baht 3,000,000; Alembic holds 99.99%.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/4a169955-8f8f-4473-a20b-99bd8fdea26c.pdf) |
| 6 Feb - USFDA final approval for Carbidopa/Levodopa/Entacapone tablets (multiple strengths) on 06 Feb 2026. | [Announcement under Regulation 30 (LODR)-Press Release / Media Release 6 Feb - USFDA final approval for Carbidopa/Levodopa/Entacapone tablets (multiple strengths) on 06 Feb 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/20dac301-2654-42d1-9e0f-1599f453ab69.pdf) |
| 6 Feb - Newspaper Publication of Unaudited Financials Results for the Quarter and Nine Months Ended 31st December, 2025 | [Announcement under Regulation 30 (LODR)-Newspaper Publication 6 Feb - Newspaper Publication of Unaudited Financials Results for the Quarter and Nine Months Ended 31st December, 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/4005dcf0-c866-4bf5-bbdc-a28bd05aad63.pdf) |
| 5 Feb - Alembic hosted audio recording of 5 Feb 2026 post-results conference call on website. | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 5 Feb - Alembic hosted audio recording of 5 Feb 2026 post-results conference call on website.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/8cc9e401-65c8-4f78-9667-24920ae9e549.pdf) |
| 27 Feb - Postal ballot: appoint Rajkumar Baheti NED from 1 April 2026; professional fees up to Rs.2.5 crore p.a. for one year. | [Shareholder Meeting / Postal Ballot-Notice of Postal Ballot 27 Feb - Postal ballot: appoint Rajkumar Baheti NED from 1 April 2026; professional fees up to Rs.2.5 crore p.a. for one year.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/c7c62a2d-13fc-47aa-a691-60bfb98bfb28.pdf) |
| 26 Feb - 26 Feb 2026 USFDA final approval for Lamotrigine ODT 25/50/100/200mg; estimated US market ~$27M. | [Announcement under Regulation 30 (LODR)-Press Release / Media Release 26 Feb - 26 Feb 2026 USFDA final approval for Lamotrigine ODT 25/50/100/200mg; estimated US market ~$27M.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/9fa59e17-6625-4a28-8a32-b19b54eebdd3.pdf) |
| 24 Feb - USFDA final approval for efinaconazole 10% ANDA; estimated market US$500M; reference Jublia. | [Announcement under Regulation 30 (LODR)-Press Release / Media Release 24 Feb - USFDA final approval for efinaconazole 10% ANDA; estimated market US$500M; reference Jublia.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/203ab902-55d8-4a62-abab-84826d6407a6.pdf) |
| 18 Feb - USFDA inspected Karakhadi injectable facility 9–18 Feb 2026; two observations, none related to data integrity. | [Completion Of United States Food And Drug Administration Inspection At Alembic Pharmaceuticals Limited'S Injectable Facility (F-3) At Karakhadi 18 Feb - USFDA inspected Karakhadi injectable facility 9–18 Feb 2026; two observations, none related to data integrity.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/65d35813-aeb6-4d87-b948-6a7e34e9d76c.pdf) |
| 13h - Management meeting with HDFC MF, TATA AIA, HDFC Life, Birla Life, ICICI Prudential on 6 March 2026 in Mumbai. | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 13h - Management meeting with HDFC MF, TATA AIA, HDFC Life, Birla Life, ICICI Prudential on 6 March 2026 in Mumbai.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/26414054-2230-4a75-a9cb-687238896856.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| Nov 2025 | [Concall - Nov 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/6924be80-9862-464e-a101-818e32429b4a.pdf) |
| Nov 2024 | [Concall - Nov 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/3a0765f9-861d-4c5a-8f07-9523c029f51f.pdf) |
| Nov 2023 | [Concall - Nov 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/f64fc1a1-c80f-462d-9ecd-04e2f8229aaf.pdf) |
| Nov 2022 | [Concall - Nov 2022](https://www.bseindia.com/xml-data/corpfiling/AttachHis/f640dfc6-50c0-495a-8a8f-5550cf2ae0b7.pdf) |
| Nov 2021 | [Concall - Nov 2021](https://www.bseindia.com/xml-data/corpfiling/AttachHis/f7d95702-c637-438a-a766-15dacf17da92.pdf) |
| May 2025 | [Concall - May 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/0aef0e86-5752-47d8-92db-937dfd500357.pdf) |
| May 2024 | [Concall - May 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/38f03d7c-fbef-489e-9535-0b88440b447e.pdf) |
| May 2023 | [Concall - May 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/7b765bfe-2685-4055-9795-d33d278ed20b.pdf) |
| May 2022 | [Concall - May 2022](https://www.bseindia.com/xml-data/corpfiling/AttachHis/56abeb04-b7f4-4450-a7a7-9f1b14c98826.pdf) |
| May 2021 | [Concall - May 2021](https://www.bseindia.com/xml-data/corpfiling/AttachHis/868ae8c2-ab6c-48ee-b5e9-bb31402d2498.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from nse | [Financial Year 2012 from nse](https://archives.nseindia.com/annual_reports/AR_APLLTD_2011_2012_11072012100526.zip) |
| from bse | [Financial Year 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/9b7dbde0-239f-4413-80ca-fce12a1dc9aa.pdf) |
| from bse | [Financial Year 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/3a9b1bd5-0975-49ac-805d-5ce7ba48a89e.pdf) |
| from bse | [Financial Year 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/d5485234-6971-4fa8-9809-7421282270a5.pdf) |
| from bse | [Financial Year 2022 from bse](https://www.bseindia.com/bseplus/AnnualReport/533573/77265533573.pdf) |
| from bse | [Financial Year 2021 from bse](https://www.bseindia.com/bseplus/AnnualReport/533573/68572533573.pdf) |
| from bse | [Financial Year 2020 from bse](https://www.bseindia.com/bseplus/AnnualReport/533573/5335730320.pdf) |
| from bse | [Financial Year 2019 from bse](https://www.bseindia.com/bseplus/AnnualReport/533573/5335730319.pdf) |
| from bse | [Financial Year 2018 from bse](https://www.bseindia.com/bseplus/AnnualReport/533573/5335730318.pdf) |
| from bse | [Financial Year 2017 from bse](https://www.bseindia.com/bseplus/AnnualReport/533573/5335730317.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T19:15:56.402Z.